Two job openings in Geneva: Establishing global governance for IACG’s recommendations

Dear All,

WHO is seeking two consultants to work for 6-12 months in Geneva. The consultants would provide strategic support and technical facilitation forestablishment of the global governance structures recommended by the UN Interagency Coordination Group on Antimicrobial Resistance (IACG, link). The work would be in close consultation with the Tripartite Organizations and other UN and international agencies.

See further details just below my signature. I have confirmed with Rosalie that (i) WHO has posted two identical roles, (ii) the term for both roles runs from early 2020 for 6 months with a possible extension to 12 months, and (iii) the deadline is 19 Dec 2019.  

Could this be you? To my eye, this looks like an excellent role if you’ve got the urge to work on antimicrobial resistance at the WHO-UN level … in this role, you’d definitely acquire insights and make connections across the entire spectrum of human and animal health.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

== Notice == 
Job openings: AMR/GCP/2020/#1 and AMR/GCP/2020/#2:
Consultancy announcement for the Department of Global Coordination and Partnership on Antimicrobial Resistance (GCP)

Contract type: Consultancy
Application Deadline:19 December 2019
Contact: Rosalie Edma
Email address:edmar@who.int
Consultancy reference: AMR/GCP/2020/#2

Purpose of consultancy: The purpose of the consultancy is to provide strategic support and technical facilitation in the establishment of the global governance structures recommended by the UN Interagency Coordination Group on Antimicrobial Resistance (IACG) in close consultation with the Tripartite Organizations and other UN and international agencies.

Background: The Department of Global Coordination and Partnership on Antimicrobial Resistance (GCP) leads and coordinates the global One Health response to antimicrobial resistance through facilitating and managing strategic and innovative partnerships and providing secretariat services to global governance mechanisms on antimicrobial resistance in collaboration with the FAO, OIE  and other UN and international agencies as well as Member States and partners including the civil society and private sector. The Department facilitates the implementation of the recommendations of the UN Interagency Coordination Group on Antimicrobial resistance, strengthen evidence-based and coordinated response against antimicrobial resistance across the One Health spectrum in humans, animals, plants, food, feed and the environment through the development and implementation of global vision, goals and targets, political advocacy and engagement, and facilitating innovative partnerships and contributes towards the achievement of the SDGs. It also promotes synergy, set priorities and advocate to unblock bottlenecks for research and development for antimicrobial resistance across the One Health spectrum.

Deliverables of the consultancy:
Task 1: Manage the coordination of the establishment of the global governance structures on antimicrobial resistance in close collaboration with the Tripartite Organizations and a wide range of stakeholders, including UN and other international organizations, member states, civil society and the private sector:

  • Deliverable 1.1: A roadmap outlining the steps of establishment of the global governance structures in close collaboration with the Tripartite organisations, member states and partners;
  • Deliverable 1.2: Conduct effective consultations to ensure transparent process in the development of the terms of reference of the governance structures through seeking efficiency and synergy;
  • Deliverable 1.3. Develop and finalise terms of refence of the structures through iterative process; 
  • Deliverable 1.4. Conduct other activities that assist the smooth establishment and running of the global governance structures.

Task 2: Promote synergy and strategic alignment of the establishment and running of the global governance structures on antimicrobial resistance with the core mandate of the Tripartite and other UN and international organizations.

  • Deliverable 2.1: Design a mechanism that facilitate the smooth establishment of the structures and monitoring of effectiveness of the processes to ensure synergy and complementarity, as well as continuous improvement;
  • Deliverable 2.2: Develop communication strategy and modus operandi for the smooth functioning of the governance structures aligned with their agreed terms of reference.

Requirements for qualifications and experiences:
Educational Qualifications:
Essential: Master’s degree in Public Health
Desirable: Degree in Medicine, Veterinary Health or Pharmacy

Experience
Essential: At least ten (10) years of public health work experience in communicable diseases.
Desirable: Experience of working in resource-constrained countries would be an asset.

Skills/Knowledge

  • Good analytical and presentation skills
  • Demonstrated capacity to write and communicate in English
  • Ability to work as part of a team, and high level of interpersonal skills
  • Good organization skills

Languages and level required
Expert ability to read, write and speak in English

Other essential requirements
Available to start the consultancy in early 2020 and no later than February 2020

Location:
The place of assignment will be WHO Headquarters, Geneva, Switzerland

Remuneration: 
The remuneration will be based on a monthly fee which is in the range US$7000 – US$9980 depending on the selected consultant’s expertise and years of experience. This is in accordance with the WHO remuneration scales for international consultants. The final monthly fee will depend upon the selected consultant’s experience and expertise. Payments will be made following satisfactory completion of a set of deliverables. In line with WHO norms, payment will be made in installments on satisfactory completion of a set of deliverables.

If you are interested to apply, please send your CV and motivational letter toedmar@who.intnot later than 19 December 2019.

Upcoming meetings of interest to the AMR community:

  • 16-18 Dec 2019 (Bangkok, Thailand): 3rd International Symposium on Alternatives to Antibiotics in Animal Production. Go here for details: https://www.ars.usda.gov/alternativestoantibiotics/
  • 16 Jan 2020 (Washington, DC): Duke-Margolis meeting entitled (approximately) “improving Payment Policies for Antibiotics.” This meeting will run 10:30am – 4:30pm ET. Go here to register.
  • 20 Feb 2020 (London, UK): Westminster Health Forum conference entitled “Antimicrobial resistance – coordinating a global response and progress on the UK strategy.” Go here for details.
  • 26-27 Feb 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 1-6 Mar 2020 (Il Ciocco, Tuscany, Italy): Gordon Research Conference (GRC) on Antibacterial Discovery and Development: “Now is the time to re-boot antibiotic R&D before it’s too little, too late.” Go here for details.
  • 12-13 Mar 2020 (Basel): BEAM-, Novo REPAIR-, CARB-X-, DZIF-, ND4BB-, ENABLE-supported (among a long list!) Conference on Novel Antimicrobials and AMR Diagnostics. Details are here, poster deadline is 12 Dec 2019.  
  • 16-17 Mar 2020 (London): BSAC Spring Conference entitled: “Bridging the gap between science, policy and effective antimicrobial use.” Go here for details. 
  • 18-21 Apr 2020 (Paris): Annual ECCMID meeting (#30)
  • 25-30 May 2020 (Rotterdam), Annual ESPID meeting (European Society for Pediatric ID, #38)
  • 27-28 Jun 2020 (Bryant University, Rhode Island): Drug Resistance Gordon Research Seminar entitled “Mechanisms and Approaches to Overcoming Drug Resistance in Cancer, Infectious Disease and Agriculture” for graduate students and postdoctoral scientists. Go here for details … this immediately precedes the GRC listed just next
  • 28 Jun-3 Jul 2020 (Bryant University, Rhode Island): Gordon Research Conference (GRC) entitled “Strategies to Disrupt Drug Resistance in Infectious Disease, Cancer and Agriculture.” Go here for details.
  • 1-4 Sep 2020 (Dublin): Annual ASM-ESCMID Conference on Antibiotic Development #5! Mark your calendar now and go here for details.
  • 9-10 Sep 2020 (Washington, DC): US PACCARB public meeting. Go here for details.
  • 22-25 Sep 2020 (Albuquerque, New Mexico): Biannual meeting of the MSGERC (Mycoses Study Group Education and Research Consortium). Save-the-date announcement is here, details to follow.
  • 17-25 Oct 2020 (Annecy, France): Interdisciplinary Course on Antibiotics and Resistance (ICARe). This is a soup-to-nuts residential course on antibiotics, antibiotic resistance, and antibiotic R&D. The course is very intense, very detailed, and gets rave reviews. The date is set for 2020 and the program will ultimately appear here. Registration is limited to 40 students and opens 15 Mar 2020.
  • 10-13 Apr 2021 (Vienna): Annual ECCMID meeting (#31)

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top